

Countermeasure without geographic limitation.

Liability immunity is afforded to manufacturers and distributors without regard to whether the countermeasure is used by or administered in any designated geographic area; liability immunity is afforded to program planners and qualified persons when the countermeasure is used by or administered in any designated geographic area, or the program planner or qualified person reasonably could have believed the recipient was in that geographic area.

## XII. Effective Time Period

### 42 U.S.C. 247d–6d(b)(2)(B)

Liability immunity for Covered Countermeasures begins on the effective date and extends for twelve (12) months from that date.

## XIII. Additional Time Period of Coverage

### 42 U.S.C. 247d–6d(b)(3)(B) and (C)

I have determined that an additional twelve (12) months of liability protection is reasonable to allow for the manufacturer(s) to arrange for disposition of the Covered Countermeasure, including return of the Covered Countermeasures to the manufacturer, and for Covered Persons to take such other actions as are appropriate to limit the administration or use of the Covered Countermeasures.

Covered Countermeasures obtained for the Strategic National Stockpile (“SNS”) during the effective period of this Declaration are covered through the date of administration or use pursuant to a distribution or release from the SNS.

## XIV. Countermeasures Injury Compensation Program

### 42 U.S.C 247d–6e

The PREP Act authorizes a Countermeasures Injury Compensation Program (“CICP”) to provide benefits to certain individuals or estates of individuals who sustain a covered serious physical injury as the direct result of the administration or use of the Covered Countermeasures, and benefits to certain survivors of individuals who die as a direct result of the administration or use of the Covered Countermeasures. The causal connection between the countermeasure and the serious physical injury must be supported by compelling, reliable, valid, medical and scientific evidence in order for the individual to be considered for compensation. The CICP is administered by the Health Resources

and Services Administration (“HRSA”), within the Department of Health and Human Services. Information about the CICP is available at the toll free number 1–855–266–2427 or <http://www.hrsa.gov/cicp/>.

## XV. Amendments

### 42 U.S.C. 247d–6d(b)(4)

Any amendments to this Declaration will be published in the **Federal Register**.

**Authority:** 42 U.S.C. 247d–6d.

**Dated:** April 9, 2015.

**Sylvia M. Burwell,**  
*Secretary.*

[FR Doc. 2015–09412 Filed 4–21–15; 8:45 am]

**BILLING CODE 4150–03–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Public Availability of the Department of Health and Human Services FY 2014 Service Contract Inventory

**AGENCY:** Office of the Assistant Secretary for Financial Resources, Office of Grants and Acquisition Policy and Accountability, Division of Acquisition, Department of Health and Human Services.

**ACTION:** Notice of Public Availability of FY 2014 Service Contract Inventories.

**SUMMARY:** In accordance with Section 743 of Division C of the Consolidated Appropriations Act of 2010 (Public Law 111–117), Department of Health and Human Services (HHS) is publishing this notice to advise the public of the availability of its FY 2014 Service Contract Inventory. This inventory provides information on service contract actions over \$25,000 that were made in FY 2014. The information is organized by function to show how contracted resources are distributed throughout the agency. The inventory has been developed in accordance with guidance issued on November 5, 2010 and December 19, 2011 by the Office of Management and Budget’s Office of Federal Procurement Policy (OFPP). OFPP’s guidance is available at <http://www.whitehouse.gov/sites/default/files/omb/procurement/memo/service-contract-inventories-guidance-11052010.pdf>. HHS has posted its inventory and a summary of the inventory on the HHS homepage at the following link: <http://www.hhs.gov/grants/servicecontracts/>.

#### FOR FURTHER INFORMATION CONTACT:

Questions regarding the service contract inventory should be directed to Lori Sakalos, Director in the HHS/Office of

the Secretary, Assistant Secretary for Financial Resources, Office of Grants and Acquisition Policy and Accountability, Office of Acquisition Policy at 202–690–6361 or [Lori.Sakalos@hhs.gov](mailto:Lori.Sakalos@hhs.gov).

**Dated:** April 16, 2015.

#### Angela Billups

*Associate Deputy Assistant Secretary for Acquisition, Senior Procurement Executive, Assistant Secretary for Financial Resources, Office of the Secretary.*

[FR Doc. 2015–09415 Filed 4–21–15; 8:45 am]

**BILLING CODE 4150–28–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; NCI EDNR Review I.

**Date:** June 9, 2015.

**Time:** 8:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

**Contact Person:** Delia Tang, MD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, MD 20850, 240–276–6456 [tangd@mail.nih.gov](mailto:tangd@mail.nih.gov).

**Name of Committee:** National Cancer Institute Initial Review Group; NCI Subcommittee F-Institutional Training and Education.

**Date:** June 9, 2015.

**Time:** 11:30 a.m. to 4:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W606, Rockville, MD 20850, (Telephone Conference Call).

**Contact Person:** Timothy C. Meeker, Ph.D., MD, Scientific Review Officer, Resource and Training Review Branch, Division of